153 related articles for article (PubMed ID: 23811569)
1. Structural requirements for potent direct inhibition of human cytochrome P450 1A1 by cannabidiol: role of pentylresorcinol moiety.
Yamaori S; Okushima Y; Masuda K; Kushihara M; Katsu T; Narimatsu S; Yamamoto I; Watanabe K
Biol Pharm Bull; 2013; 36(7):1197-203. PubMed ID: 23811569
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol.
Yamaori S; Okushima Y; Yamamoto I; Watanabe K
Chem Biol Interact; 2014 May; 215():62-8. PubMed ID: 24667653
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol induces expression of human cytochrome P450 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells.
Yamaori S; Kinugasa Y; Jiang R; Takeda S; Yamamoto I; Watanabe K
Life Sci; 2015 Sep; 136():87-93. PubMed ID: 26187180
[TBL] [Abstract][Full Text] [Related]
4. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.
Yamaori S; Ebisawa J; Okushima Y; Yamamoto I; Watanabe K
Life Sci; 2011 Apr; 88(15-16):730-6. PubMed ID: 21356216
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19.
Jiang R; Yamaori S; Okamoto Y; Yamamoto I; Watanabe K
Drug Metab Pharmacokinet; 2013; 28(4):332-8. PubMed ID: 23318708
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.
Yamaori S; Okamoto Y; Yamamoto I; Watanabe K
Drug Metab Dispos; 2011 Nov; 39(11):2049-56. PubMed ID: 21821735
[TBL] [Abstract][Full Text] [Related]
7. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes.
Yamaori S; Kushihara M; Yamamoto I; Watanabe K
Biochem Pharmacol; 2010 Jun; 79(11):1691-8. PubMed ID: 20117100
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol-2',6'-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15-lipoxygenase inhibitor.
Takeda S; Usami N; Yamamoto I; Watanabe K
Drug Metab Dispos; 2009 Aug; 37(8):1733-7. PubMed ID: 19406952
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cannabidiol-mediated cytochrome P450 inactivation.
Bornheim LM; Everhart ET; Li J; Correia MA
Biochem Pharmacol; 1993 Mar; 45(6):1323-31. PubMed ID: 8466552
[TBL] [Abstract][Full Text] [Related]
10. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids.
Zhai S; Dai R; Friedman FK; Vestal RE
Drug Metab Dispos; 1998 Oct; 26(10):989-92. PubMed ID: 9763404
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro metabolism of cannabidiol monomethyl ether and cannabidiol dimethyl ether in the guinea pig: on the formation mechanism of cannabielsoin-type metabolite from cannabidiol.
Gohda H; Narimatsu S; Yamamoto I; Yoshimura H
Chem Pharm Bull (Tokyo); 1990 Jun; 38(6):1697-701. PubMed ID: 2208386
[TBL] [Abstract][Full Text] [Related]
12. Self-catalyzed inactivation of cytochrome P-450 during microsomal metabolism of cannabidiol.
Watanabe K; Arai M; Narimatsu S; Yamamoto I; Yoshimura H
Biochem Pharmacol; 1987 Oct; 36(20):3371-7. PubMed ID: 3675599
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin.
Chun YJ; Ryu SY; Jeong TC; Kim MY
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):389-93. PubMed ID: 11259321
[TBL] [Abstract][Full Text] [Related]
14. Antiepileptic potential of cannabidiol analogs.
Consroe P; Martin A; Singh V
J Clin Pharmacol; 1981; 21(S1):428S-436S. PubMed ID: 7298873
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol is a selective human cytochrome P450 1A1 inhibitor.
Chun YJ; Kim MY; Guengerich FP
Biochem Biophys Res Commun; 1999 Aug; 262(1):20-4. PubMed ID: 10448061
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling.
Lo SN; Chang YP; Tsai KC; Chang CY; Wu TS; Ueng YF
Toxicol Appl Pharmacol; 2013 Nov; 272(3):671-80. PubMed ID: 23886934
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons.
Shimada T; Guengerich FP
Chem Res Toxicol; 2006 Feb; 19(2):288-94. PubMed ID: 16485905
[TBL] [Abstract][Full Text] [Related]
18. Identification of Potent and Selective CYP1A1 Inhibitors via Combined Ligand and Structure-Based Virtual Screening and Their in Vitro Validation in Sacchrosomes and Live Human Cells.
Joshi P; McCann GJP; Sonawane VR; Vishwakarma RA; Chaudhuri B; Bharate SB
J Chem Inf Model; 2017 Jun; 57(6):1309-1320. PubMed ID: 28489395
[TBL] [Abstract][Full Text] [Related]
19. Development of flavone propargyl ethers as potent and selective inhibitors of cytochrome P450 enzymes 1A1 and 1A2.
Sridhar J; Ellis J; Dupart P; Liu J; Stevens CL; Foroozesh M
Drug Metab Lett; 2012; 6(4):275-84. PubMed ID: 23506553
[TBL] [Abstract][Full Text] [Related]
20. Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
Lee D; Perez P; Jackson W; Chin T; Galbreath M; Fronczek FR; Isovitsch R; Iimoto DS
Bioorg Med Chem Lett; 2016 Jul; 26(14):3243-3247. PubMed ID: 27265259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
